Fig. 1From: Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapyHuman colon cancer cells are sensitive to GP130 inhibition. a: The expression of GP130, IL-11, IL-11Rα, IL-6, IL-6R, p-STAT3(Y705) and ER-α was evaluated in colon cancer cells. DLD-1, HCT-116, and HCT-15 cells were harvested, and the protein expression was detected by western blot. GAPDH served as a loading control. b: 5000 cells per well of DLD-1, HCT-15 and HCT-116 cells were seeded in 96-well plates and treated with neutralized GP130 antibody at 50 ng/ml in 2% FBS medium for 48 h. The IgG antibody at the same concentration served as a control. Cell viability was measured by MTT assay. (***, p < 0.001)Back to article page